Avanos Medical : Submission of Matters to a Vote of Security Holders - Form 8-K
April 29, 2024 at 03:34 pm
Share
Item 5.07 Submission of Matters to a Vote of Security Holders
The 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting") of Avanos Medical, Inc. (the "Company") was held on April 25, 2024 at the Company's headquarters in Alpharetta, Georgia. A total of 42,989,866 shares of the Company's common stock were represented at the 2024 Annual Meeting in person or by proxy, constituting approximately 93.04% of the outstanding shares entitled to vote at the 2024 Annual Meeting.
At the 2024 Annual Meeting, the Company's stockholders voted on the following matters, which are described in detail in the proxy statement filed by the Company with the Securities and Exchange Commission on March 15, 2024:
1.To elect Gary D. Blackford, Dr. Lisa Egbuonu-Davis, Patrick J. O'Leary, Dr. Julie Shimer and Joseph F. Woody to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders ("Proposal No. 1");
2.To ratify the appointment of Deloitte & Touche LLP as the Company's independent auditors for 2024 ("Proposal No. 2"); and
3.To approve, on an advisory basis, the compensation of the Company's named executive officers, or NEOs ("Proposal No. 3").
Proposal No. 1.The Company's stockholders approved the nominees recommended for election in Proposal No. 1. The votes cast on Proposal No. 1 were as follows:
Director
For
Withhold
Broker non-votes
Gary D. Blackford
39,916,596
760,475
2,312,795
Dr. Lisa Egbuonu-Davis
39,845,016
832,055
2,312,795
Patrick J. O'Leary
40,149,326
527,745
2,312,795
Dr. Julie Shimer
39,726,238
950,833
2,312,795
Joseph F. Woody
40,385,119
291,952
2,312,795
Proposal No. 2. The Company's stockholders approved Proposal No. 2. The votes cast on Proposal No. 2 were as follows:
For
Against
Abstain
Appointment of Deloitte & Touche LLP
42,503,768
435,813
50,285
Proposal No. 3. The Company's stockholders approved Proposal No. 3. The votes cast on Proposal No. 3 were as follows:
For
Against
Abstain
Broker non-votes
Approval of NEO compensation
38,515,084
2,104,432
57,555
2,312,795
Attachments
Original Link
Permalink
Disclaimer
Avanos Medical Inc. published this content on
29 April 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
29 April 2024 14:33:24 UTC.
Avanos Medical, Inc. is a medical device company, which is focused on delivering solutions. The Company offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Company conducts its business in one segment that provides its medical device products to healthcare providers and patients globally with manufacturing facilities in the United States and Mexico. Its digestive health products include MIC-KEY enteral feeding tubes, Corpak patient feeding solutions and NeoMed neonatal and pediatric feeding solutions. The Companyâs acute pain products include ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems. The Company's interventional pain solutions include COOLIEF pain therapy and OrthogenRxs knee osteoarthritis pain relief injection products.